Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 11/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27683398 | 0.86 | GABRA5 (0.55) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| SCHEMBL29203444 | 0.84 | GABRA5 (0.46) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| SCHEMBL6987 | 0.84 | GABRA5 (0.50) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| SCHEMBL256699 | 0.84 | PTGS1 (0.59) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| SCHEMBL21834100 | 0.83 | GABRA5 (0.49) | PTGS1PTGS2GABRA5ALDH1A1KMT2A | |
| SCHEMBL195699 | 0.82 | PTGS1 (0.58) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| SCHEMBL107436 | 0.82 | PTGS1 (0.58) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| SCHEMBL286436 | 0.82 | PTGS1 (0.58) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| SCHEMBL12844155 | 0.81 | PTGS1 (0.56) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| Water SCHEMBL27477176 | 0.81 | PTGS1 (0.56) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346798-B2 | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors | AMGEN INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150057271-A1 | DIHYDROBENZOXAZINE AND TETRAHYDROQUINOXALINE SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2015-02-26 | — | — | US | disclosed |
| EP-2690095-A1 | Aryl gpr120 receptor agonists and uses thereof | Camabay Therapeutics, Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| WO-2013122897-A1 | DIHYDROBENZOXAZINE AND TETRAHYDROQUINOXALINE SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| US-8329727-B2 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8236963-B2 | Tricyclic spiro derivatives as CRTH2 modulators | MERCK SERONO SA (CH) | 2012-08-07 | — | — | US | disclosed |
| EP-2454264-A1 | TRICYCLIC INDOLE-DERIVED SPIRO DERIVATIVES AS CRTH2 MODULATORS | Merck Serono S.A. (CH) | 2012-05-23 | — | — | EP | disclosed |
| EP-2454243-A2 | TETRAZOLE DERIVATIVES | Merck Serono SA (CH) | 2012-05-23 | — | — | EP | disclosed |
| US-20120115895-A1 | TRICYCLIC INDOLE-DERIVED SPIRO DERIVATIVES AS CRTH2 MODULATORS | MERCK SERONO S.A. (CH) | 2012-05-10 | — | — | US | disclosed |
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2012-05-10 | — | — | US | disclosed |
| US-20080153802-A1 | Alpha-helical mimetics | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-06-26 | — | — | US | disclosed |
| EP-1891075-A1 | TRICYCLIC SPIRO DERIVATIVES AS CRTH2 MODULATORS | LABORATOIRES SERONO S.A. (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| EP-1802566-A1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| US-20070135416-A1 | Tricyclic amide derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2007065820-A1 | TRICYCLIC AMIDE DERIVATIVES USEFUL FOR TREATING OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| WO-2006125784-A1 | TRICYCLIC SPIRO DERIVATIVES AS CRTH2 MODULATORS | LABORATOIRES SERONO S.A. (CH) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006037480-A1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074115-A1 | Novel hexafluoroisopropanol substituted ether derivatives | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135416-A1 | Tricyclic amide derivatives | HRH4, HRH3, HCAR1 | PTGS1 732/4885PTGS2 1161/4885GABRA5 332/4885 |
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | TSLP, IL5, CMA1 | PTGS1 220/4885PTGS2 365/4885GABRA5 326/4885 |
| US-20150057271-A1 | DIHYDROBENZOXAZINE AND TETRAHYDROQUINOXALINE SODIUM CHANNEL INHIBITORS | SCN5A, KCNH1, KCNQ5 | PTGS1 289/4885PTGS2 381/4885GABRA5 404/4885 |
| US-20060074115-A1 | Novel hexafluoroisopropanol substituted ether derivatives | NR1H3, NR1H2, NR1I2 | PTGS1 2953/4885PTGS2 3693/4885GABRA5 987/4885 |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | ZC3HAV1, TPMT, DPP4 | PTGS1 1364/4885PTGS2 2185/4885GABRA5 1567/4885 |
| US-20080153802-A1 | Alpha-helical mimetics | BID, BAX, BAD | PTGS1 2822/4885PTGS2 2941/4885GABRA5 2324/4885 |
| US-20120115895-A1 | TRICYCLIC INDOLE-DERIVED SPIRO DERIVATIVES AS CRTH2 MODULATORS | HRH2, HRH1, LTC4S | PTGS1 79/4885PTGS2 44/4885GABRA5 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.